SBIR/STTR Research Award

improving Cas9 mediated homologous recombination in pluripotent stem cells

Award identifier e2a512f8fa366577f0be0799eb3d39436dd41dc30e08a8fecd9a2ffc4c79d6d0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,518

Program and phase

STTR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
APPLIED STEMCELL, INC.
Proposal award date
2016-02-01
Contract end date
2017-01-31
UEI
SSENYXM7HCF1
Solicitation number
PA14-072
Topic code
200

Research abstract

DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription Activator Like Effector Nucleases TALENs and CRISPR clustered regularly interspaced short palindromic repeats associated protein Cas have enabled high efficient gene knockout KO in pluripotent stem cells in humans and model animal species Indeed these meganucleases especially Cas are becoming the mainstream choice for gene targeting in stem cells and in transgenic animal production However the knock in efficiency remains to be further improved even in the presence of these meganucleases We hypothesize that inhibiting non homologous end joining NHEJ and or enhancing the homology directed repair HDR via small molecules will improve the meganuclease mediated knock in efficiency in pluripotent stem cells In this project we will test the feasibility by screening smll molecules using a reporter cell line to identify candidate compounds followed by validation of the efficacy of these compounds in human iPSCs In Aim we will first establish a reporter cell line that will express luciferase upon successful Ca mediated homologous recombination HR We will then screen small molecule compounds on this reporter cell line After identifying candidate compounds in Aim we will validate their efficacy on human induced PSCs iPSCs in Aim We will work to determine the Cas mediated knock in efficiency in gene correction on multiple human iPSC lines using candidate compounds identified in Aim This proposal aims to address a bottleneck problem in regenerative medicine i e low knock in efficiency in PSCs Its success will have significant impacts on the entire field as a majority o stem cell based therapy will require targeted gene modifications Notably it may even enable multiplex gene corrections in human PSCs PUBLIC HEALTH RELEVANCE Emerging technologies such as CRISPR clustered regularly interspaced short palindromic repeats associated protein Cas have enabled high efficient gene knockout KO in pluripotent stem cells in humans and model animal species However the knock in efficiency remains to be further improved even in the presence of these meganucleases We propose to screen small molecule library on a reporter cell line to identify candidate compound that can dramatically improve the efficiency of Cas mediated homologous recombination

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2014–2020). Reported award amounts total $3,886,211. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.